All In Biotech

Free tool

FAERS Monitor: Imfinzi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761069 or its brand name (Imfinzi, Durvalumab). Reports on generic versions are filed under their own applications.

Reports

21,581

Serious

20,621

96% of reports

Hospitalization

6,299

Death reported

6,844

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death4,160
  • malignant neoplasm progression1,703
  • pneumonitis900
  • radiation pneumonitis812
  • diarrhoea700
  • pyrexia670
  • off label use616
  • pneumonia500
  • dyspnoea495
  • interstitial lung disease491
  • fatigue484
  • asthenia478
  • anaemia477
  • rash460
  • neutrophil count decreased420

Reports by year received

View as table
YearReports
20168
2017168
2018769
20191,362
20201,456
20211,718
20221,511
20232,836
20243,709
20254,001
20264,043

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,032,578 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
radiation pneumonitisSignal812595.0545.8298,648
pneumonitisSignal90033.331.227,251
malignant neoplasm progressionSignal1,70316.515.724,428
neutrophil count decreasedSignal42010.19.23,421
interstitial lung diseaseSignal49110.09.13,924
deathSignal4,1604.74.612,669
anaemiaSignal4772.42.2407
pyrexia6701.91.8283
pneumonia5001.51.486
asthenia4781.21.122
diarrhoea7001.11.02
rash4601.00.90
dyspnoea4950.90.813
off label use6160.70.692
fatigue4840.60.6129

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.